Lifecore Biomedical, Inc. (LFCR)
(Delayed Data from NSDQ)
$7.41 USD
+0.42 (6.01%)
Updated Aug 4, 2025 03:59 PM ET
After-Market: $7.43 +0.02 (0.27%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LFCR 7.41 +0.42(6.01%)
Will LFCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LFCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LFCR
Lifecore Biomedical (LFCR) Reports Q3 Loss, Misses Revenue Estimates
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates
LFCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lifecore Biomedical (LFCR) Reports Q2 Loss, Tops Revenue Estimates
Other News for LFCR
Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August ...
Laughing Water Capital Q2 2025 Letter
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | LFCR Stock News
Stock Picks From Seeking Alpha's June 2025 New Analysts
Lifecore Biomedical: Inflecting Financials Over Next 3 Years